Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase I Clinical Trial of GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T) for the Treatment of Patients With Advanced Hepatocellular Carcinoma
Conditions
Interventions
Super CAR-T
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, Gaungdong, China
Start Date
March 20, 2026
Primary Completion Date
April 30, 2028
Completion Date
July 30, 2028
Last Updated
March 25, 2026
NCT07039201
NCT07242417
NCT06737913
NCT04523493
NCT07282509
NCT01101906
Lead Sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions